<DOC>
	<DOCNO>NCT00006267</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness nitrocamptothecin treat patient recurrent metastatic ovarian epithelial primary peritoneal cancer .</brief_summary>
	<brief_title>Nitrocamptothecin Treating Patients With Recurrent Metastatic Ovarian Epithelial Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity nitrocamptothecin patient recurrent metastatic ovarian epithelial primary peritoneal cancer . - Determine nature degree toxicity regimen patient . OUTLINE : Patients receive oral nitrocamptothecin day 1-5 . Treatment continue every 7 day absence disease progression unacceptable toxicity . Patients follow 2 week , every 3 month 2 year , every 6 month 3 year . PROJECTED ACCRUAL : Approximately 19-51 patient accrue study within 22 month .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent metastatic ovarian epithelial primary peritoneal cancer Measurable disease Ascites pleural effusion consider measurable Sonography allow bidimensionally measurable Must eligible high priority GOG protocol PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Granulocyte count least 1,500/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT alkaline phosphatase great 3 time ULN Renal : Creatinine great 2.0 mg/dL Other : No prior concurrent invasive malignancy past 5 year except nonmelanoma skin cancer No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 2 prior chemotherapy regimen contain carboplatin , cisplatin , another organoplatinum compound combine paclitaxel Second line therapy may include agent except topoisomerase I inhibitor ( i.e. , topotecan ) No prior nitrocamptothecin topoisomerase I inhibitors At least 3 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : At least 3 week since prior surgery recover Other : No prior cancer therapy contraindicate study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>